Abstract
Aim: To investigate the presence/absence of the Chr-11 tRNA-Lys-CUU gene as a marker for genetic predisposition to Type 2 diabetes mellitus (T2DM). Methods: We enrolled 122 patients diagnosed with T2DM and 77 non-diabetic individuals. We evaluated clinical and biochemical parameters (body mass index, hypertension, cholesterol levels, glycosylated hemoglobin, triglycerides, etc.), and performed a genotypic profiling of Chr-11 tRNA-Lys-CUU by polymerase chain reaction analyses. Results: Approximately one third of the population lacked Chr-11 tRNA-Lys-CUU. We did not observe a statistically significant association between the presence/absence of Chr-11 tRNA-Lys-CUU and T2DM. Conclusion: The genotypic distribution of Chr-11 tRNA-Lys-CUU in our population was consistent to that reported by others. This gene failed as a marker for T2DM predisposition.
Author contributions
P Yang and NW Soria performed experiments; NW Soria, DM Beltramo, LR de Pouplana and AG Torres analyzed data; NW Soria supervised research; AG Torres: conceived the study; and wrote the manuscript with input from all authors.
Acknowledgements
The authors thank the patients for their cooperation and for providing blood samples for the study. The authors thank V Ojeda and J Luna for their medical support.
Financial & competing interests disclosure
The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Grants from Universidad Católica de Córdoba to NW Soria Grant by the Spanish Ministry of Economy and Competitiveness (BIO2015-64572) to LR de Pouplana. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.
Ethical conduct of research
The authors state that they have obtained appropriate institutional review board approval or have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations. In addition, for investigations involving human subjects, informed consent has been obtained from the participants involved..